Fritextsökning
Innehållstyper
-
Your solution for right part positioning
ZEISS OmniFix CT - right part positioning solution to get meaningful measuring results for all part sizes.
-
FDA approves Gilead’s HIV injection: “Historic day”
Gilead Sciences’ preventive HIV drug, lenacapavir, was approved on Wednesday by the U.S. Food and Drug Administration (FDA), sparking new hope for finally break...
-
Automated nitrogen analysis reduces costs per sample
N-Realizer analytical system from C. Gerhardt increases productivity with valve block from Festo
-
Astra Zeneca miljardsatsar på Crispr och AI för läkemedelsutveckling
Astra Zeneca har tecknat avtal med San Francisco-baserade Algen Biotechnologies, som specialiserat sig på artificiell intelligens och genredigering.
-
FDA’s new CSA guidance: transforming software validation for production and quality systems
FDA’s final guidance on Computer Software Assurance (CSA) for Production and Quality System Software marks a significant modernization of software validation practices.
-
To build trust, one must be able to say “I don’t know” – whether human or AI
Will AI strengthen or break down trust? It depends on whether we can understand and accept its limitations, and our own, writes Sarah Lidé in a column.
-
Eli Lilly tecknar miljardavtal med AI-bolag för fetmaforskning
Eli Lilly har tecknat ett mångmiljardavtal med startupen Superluminal Medicines som använder AI för upptäcka och utveckla småmolekylära läkemedel för behandling...
-
ZEISS introduces the new Smartzoom 100
The future of digital microscopy for efficient optical inspections.
-
After the threat of tariffs – Novartis invests 230 billion in the USA
Pharmaceutical giant Novartis plans to invest 23 billion dollarsover the next five years to expand its production in the USA. The goal is for all medicines dest...
-
The Top 10 Challenges Facing Laboratories Today
Navigating the Laboratory Automation Landscape
-
Gothenburg, the city of life science – We are ‘Little Boston’
Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other in...
-
Canada approves leqembi as global alzheimer’s drug race heats up
Leqembi has secured approval in Canada, further consolidating its global lead among disease-modifying Alzheimer’s therapies. The antibody is now authorized in 1...
-
Motgång för nästa generationens icke-opioida smärtstillare
Vertex Pharmaceuticals avbryter utvecklingen av den icke-opioida smärtstillaren VX-993 som monoterapi efter ett misslyckande i en fas II-studie.
-
Karriärcoachen: Så får du AI att söka jobbet åt dig
För att använda AI effektivt måste vi ändra vårt tankesätt för hur vi kommunicerar. Annars får vi bara döda motivationsbrev och döda resuméer. Det anser karriär...
-
Advancing Drug Discovery by Combining Complex In-Vitro Models with AI-Powered 3D/4D Image Analysis
Free webinar organized by ZEISS.
-
Who pays for Rebecca Doe – and all of us?
Anna Törner on how easily we get used to the idea that healthcare is free - when it really is about how and who pays for it
-
Scientific Solutions
-
Explore our tailored program for Control 2025
Choose an innovation tour, or join our industry-specific guided tours.
-
The scientist behind Novo Nordisk's obesity success: “I never stopped believing in GLP-1”
It took several years of failures in GLP-1 before Lotte Bjerre Knudsen and her colleagues found the right path – but when they did, it was a true breakthrough. ...
-
Scale Up Your Image Analysis
ZEISS arivis Hub for accelerated analysis and faster results.
-
The top five most expensive drugs in 2025
New advanced therapeutic medicines are reaching the market, but their price tags remain exceptionally high. This year’s ranking of the most expensive drugs in t...
-
ZEISS Hosts an exceptional Global Conference on Innovation and Production in Berlin
More than 50 distinguished speakers from leading manufacturing companies.
-
Large study: The benefits and risks of obesity medications
Medications such as Ozempic can reduce the risk of a range of different diseases and health conditions but also increase the risk of others. This is according t...
-
Björn Arvidsson will lead research and innovation in Region Uppsala
The Swedish life science profile Björn Arvidsson has been appointed Director of Research and Innovation for Region Uppsala.